3zyx Citations

The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition.

FEBS J 278 4860-9 (2011)

Abstract

The major structural difference between human monoamine oxidases A (MAO A) and B (MAO B) is that MAO A has a monopartite substrate cavity of ~550 Å(3) volume and MAO B contains a dipartite cavity structure with volumes of ~290 Å(3) (entrance cavity) and ~400 Å(3) (substrate cavity). Ile199 and Tyr326 side chains separate these two cavities in MAO B. To probe the function of these gating residues, Ile199Ala and Ile199Ala-Tyr326Ala mutant forms of MAO B were investigated. Structural data on the Ile199Ala MAO B mutant show no alterations in active site geometries compared with wild-type enzyme while the Ile199Ala-Tyr326Ala MAO B mutant exhibits alterations in residues 100-103 which are part of the loop gating the entrance to the active site. Both mutant enzymes exhibit catalytic properties with increased amine K(M) but unaltered k(cat) values. The altered K(M) values on mutation are attributed to the influence of the cavity structure in the binding and subsequent deprotonation of the amine substrate. Both mutant enzymes exhibit weaker binding affinities relative to wild-type enzyme for small reversible inhibitors. Ile199Ala MAO B exhibits an increase in binding affinity for reversible MAO B specific inhibitors which bridge both cavities. The Ile199Ala-Tyr326Ala double mutant exhibits inhibitor binding properties more similar to those of MAO A than to MAO B. These results demonstrate that the bipartite cavity structure in MAO B plays an important role in substrate and inhibitor recognition to distinguish its specificities from those of MAO A and provide insights into specific reversible inhibitor design for these membrane-bound enzymes.

Articles - 3zyx mentioned but not cited (1)

  1. The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. Milczek EM, Binda C, Rovida S, Mattevi A, Edmondson DE. FEBS J 278 4860-4869 (2011)


Reviews citing this publication (13)

  1. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Finberg JP. Pharmacol Ther 143 133-152 (2014)
  2. Gates of enzymes. Gora A, Brezovsky J, Damborsky J. Chem Rev 113 5871-5923 (2013)
  3. Enzyme Tunnels and Gates As Relevant Targets in Drug Design. Marques SM, Daniel L, Buryska T, Prokop Z, Brezovsky J, Damborsky J. Med Res Rev 37 1095-1139 (2017)
  4. Kinetics, mechanism, and inhibition of monoamine oxidase. Ramsay RR, Albreht A. J Neural Transm (Vienna) 125 1659-1683 (2018)
  5. Monoamine oxidases in development. Wang CC, Billett E, Borchert A, Kuhn H, Ufer C. Cell Mol Life Sci 70 599-630 (2013)
  6. Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches. Hong R, Li X. Medchemcomm 10 10-25 (2019)
  7. Monoamine oxidase A and B substrates: probing the pathway for drug development. Chajkowski-Scarry S, Rimoldi JM. Future Med Chem 6 697-717 (2014)
  8. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches. Duarte P, Cuadrado A, León R. Handb Exp Pharmacol 264 229-259 (2021)
  9. Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches. Cruz-Vicente P, Passarinha LA, Silvestre S, Gallardo E. Molecules 26 2193 (2021)
  10. The structure of monoamine oxidases: past, present, and future. Iacovino LG, Magnani F, Binda C. J Neural Transm (Vienna) 125 1567-1579 (2018)
  11. On the practical aspects of characterising monoamine oxidase inhibition in vitro. Holt A. J Neural Transm (Vienna) 125 1685-1705 (2018)
  12. Structure-Based Specific Detection and Inhibition of Monoamine Oxidases and Their Applications in Central Nervous System Diseases. Shi R, Wu Q, Xin C, Yu H, Lim KL, Li X, Shi Z, Zhang CW, Qian L, Li L, Huang W. Chembiochem 20 1487-1497 (2019)
  13. Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer's disease. Zou D, Liu R, Lv Y, Guo J, Zhang C, Xie Y. J Enzyme Inhib Med Chem 38 2270781 (2023)

Articles citing this publication (24)

  1. Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. Murugan NA, Chiotis K, Rodriguez-Vieitez E, Lemoine L, Ågren H, Nordberg A. Eur J Nucl Med Mol Imaging 46 1369-1382 (2019)
  2. What a Difference a Methyl Group Makes: The Selectivity of Monoamine Oxidase B Towards Histamine and N-Methylhistamine. Maršavelski A, Vianello R. Chemistry 23 2915-2925 (2017)
  3. Inhibition of monoamine oxidase by derivatives of piperine, an alkaloid from the pepper plant Piper nigrum, for possible use in Parkinson's disease. Al-Baghdadi OB, Prater NI, Van der Schyf CJ, Geldenhuys WJ. Bioorg Med Chem Lett 22 7183-7188 (2012)
  4. Do MAO A and MAO B utilize the same mechanism for the C-H bond cleavage step in catalysis? Evidence suggesting differing mechanisms. Orru R, Aldeco M, Edmondson DE. J Neural Transm (Vienna) 120 847-851 (2013)
  5. Microbial Metabolite Urolithin B Inhibits Recombinant Human Monoamine Oxidase A Enzyme. Singh R, Chandrashekharappa S, Vemula PK, Haribabu B, Jala VR. Metabolites 10 E258 (2020)
  6. Stereoselective Activity of 1-Propargyl-4-styrylpiperidine-like Analogues That Can Discriminate between Monoamine Oxidase Isoforms A and B. Knez D, Colettis N, Iacovino LG, Sova M, Pišlar A, Konc J, Lešnik S, Higgs J, Kamecki F, Mangialavori I, Dolšak A, Žakelj S, Trontelj J, Kos J, Binda C, Marder M, Gobec S. J Med Chem 63 1361-1387 (2020)
  7. Recognition dynamics of dopamine to human Monoamine oxidase B: role of Leu171/Gln206 and conserved water molecules in the active site cavity. Dasgupta S, Mukherjee S, Mukhopadhyay BP, Banerjee A, Mishra DK. J Biomol Struct Dyn 36 1439-1462 (2018)
  8. Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques. Rojas RJ, Edmondson DE, Almos T, Scott R, Massari ME. Bioorg Med Chem 23 770-778 (2015)
  9. Exploring 4-substituted-2-thiazolylhydrazones from 2-, 3-, and 4-acetylpyridine as selective and reversible hMAO-B inhibitors. Chimenti P, Petzer A, Carradori S, D'Ascenzio M, Silvestri R, Alcaro S, Ortuso F, Petzer JP, Secci D. Eur J Med Chem 66 221-227 (2013)
  10. Monoamine oxidase (MAO) inhibitory activity: 3-phenylcoumarins versus 4-hydroxy-3-phenylcoumarins. Delogu GL, Serra S, Quezada E, Uriarte E, Vilar S, Tatonetti NP, Viña D. ChemMedChem 9 1672-1676 (2014)
  11. Coumarin-Chalcone Hybrids as Inhibitors of MAO-B: Biological Activity and In Silico Studies. Moya-Alvarado G, Yañez O, Morales N, González-González A, Areche C, Núñez MT, Fierro A, García-Beltrán O. Molecules 26 2430 (2021)
  12. Why does the Y326I mutant of monoamine oxidase B decompose an endogenous amphetamine at a slower rate than the wild type enzyme? Reaction step elucidated by multiscale molecular simulations. Pregeljc D, Jug U, Mavri J, Stare J. Phys Chem Chem Phys 20 4181-4188 (2018)
  13. COVID-19 infection and neurodegeneration: Computational evidence for interactions between the SARS-CoV-2 spike protein and monoamine oxidase enzymes. Hok L, Rimac H, Mavri J, Vianello R. Comput Struct Biotechnol J 20 1254-1263 (2022)
  14. Computational Drug Target Screening through Protein Interaction Profiles. Vilar S, Quezada E, Uriarte E, Costanzi S, Borges F, Viña D, Hripcsak G. Sci Rep 6 36969 (2016)
  15. Promising Non-cytotoxic Monosubstituted Chalcones to Target Monoamine Oxidase-B. Iacovino LG, Pinzi L, Facchetti G, Bortolini B, Christodoulou MS, Binda C, Rastelli G, Rimoldi I, Passarella D, Di Paolo ML, Dalla Via L. ACS Med Chem Lett 12 1151-1158 (2021)
  16. Design, synthesis, and evaluation of 3,7-substituted coumarin derivatives as multifunctional Alzheimer's disease agents. Mzezewa SC, Omoruyi SI, Zondagh LS, Malan SF, Ekpo OE, Joubert J. J Enzyme Inhib Med Chem 36 1607-1621 (2021)
  17. Novel polyamine analogues: from substrates towards potential inhibitors of monoamine oxidases. Bonaiuto E, Milelli A, Cozza G, Tumiatti V, Marchetti C, Agostinelli E, Fimognari C, Hrelia P, Minarini A, Di Paolo ML. Eur J Med Chem 70 88-101 (2013)
  18. Synthesis, Biological Evaluation and Molecular Modeling Studies of Propargyl-Containing 2,4,6-Trisubstituted Pyrimidine Derivatives as Potential Anti-Parkinson Agents. Kumar B, Kumar M, Dwivedi AR, Kumar V. ChemMedChem 13 705-712 (2018)
  19. Why p-OMe- and p-Cl-β-Methylphenethylamines Display Distinct Activities upon MAO-B Binding. Fierro A, Edmondson DE, Celis-Barros C, Rebolledo-Fuentes M, Zapata-Torres G. PLoS One 11 e0154989 (2016)
  20. In silico studies of natural product-like caffeine derivatives as potential MAO-B inhibitors/AA2AR antagonists for the treatment of Parkinson's disease. Boulaamane Y, Ibrahim MAA, Britel MR, Maurady A. J Integr Bioinform 19 (2022)
  21. Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades. Herrera-Arozamena C, Estrada-Valencia M, López-Caballero P, Pérez C, Morales-García JA, Pérez-Castillo A, Sastre ED, Fernández-Mendívil C, Duarte P, Michalska P, Lombardía J, Senar S, León R, López MG, Rodríguez-Franco MI. J Med Chem 65 4727-4751 (2022)
  22. Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's Disease. Duarte P, Michalska P, Crisman E, Cuadrado A, León R. Antioxidants (Basel) 11 247 (2022)
  23. Isatin-based benzyloxybenzene derivatives as monoamine oxidase inhibitors with neuroprotective effect targeting neurogenerative disease treatment. Benny F, Oh JM, Kumar S, Abdelgawad MA, Ghoneim MM, Abdel-Bakky MS, Kukerti N, Jose J, Kim H, Mathew B. RSC Adv 13 35240-35250 (2023)
  24. Modified Tacrine Derivatives as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Synthesis, Biological Evaluation, and Molecular Modeling Study. Fares S, El Husseiny WM, Selim KB, Massoud MAM. ACS Omega 8 26012-26034 (2023)